<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241549</url>
  </required_header>
  <id_info>
    <org_study_id>CR108732</org_study_id>
    <secondary_id>74494550AML1002</secondary_id>
    <nct_id>NCT04241549</nct_id>
  </id_info>
  <brief_title>A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment</brief_title>
  <official_title>A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety&#xD;
      profile of cusatuzumab in combination with azacitidine in Japanese participants with&#xD;
      treatment na√Øve acute myeloid leukemia (AML) who are not candidates for intensive treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Actual">July 19, 2021</completion_date>
  <primary_completion_date type="Actual">July 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of participants with AEs and SAEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of Participants with Dose-Limiting Toxicity (DLTs)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Number of participants with DLTs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Severity of DLT as assessed by NCI-CTCAE in participants will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Percentage of Participants with Complete Response (CR)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Percentage of participants with complete response based on response criteria per investigator assessment in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>ORR is defined as percentage of participants with CR, CRh and CRi based on response criteria per investigator assessment in participants with AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>ORR is defined as the percentage of participants with CR, partial response (PR) and marrow CR based on response criteria per investigator assessment in participants with MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of Participants with Hematologic Improvement (HI)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Percentage of participants with hematologic improvement will be reported according to response criteria per investigator assessment in participants with MDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Time to Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to response is defined as time from first dose to achieving the first response of CR, CRh, or CRi in participants with AML and CR, PR or marrow CR in participants with MDS..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response is defined as time from achieving the first response of CR, CRh, or CRi in participants with AML and CR, PR or marrow CR in participants with MDS to hematologic relapse or death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Red Blood Cell (RBC) or Platelets Transfusion Independence</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS is defined as the time from initial study intervention administration to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Maximum Serum Concentration (Cmax) of Cusatuzumab</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cmax is the maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Serum Trough Concentration (Ctrough) of Cusatuzumab</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Ctrough is the serum concentration immediately prior to the next drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Part 1 (Dose Finding): Cusatuzumab + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with acute myeloid leukemia (AML) will receive cusatuzumab intravenously (IV) in combination with azacitidine subcutaneously (SC) or IV. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion): Cusatuzumab + Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) will receive cusatuzumab intravenously (IV) at the recommended Phase 2 dose (RP2D) determined in Part 1 in combination with azacitidine subcutaneously (SC) or IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cusatuzumab</intervention_name>
    <description>Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.</description>
    <arm_group_label>Part 1 (Dose Finding): Cusatuzumab + Azacitidine</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion): Cusatuzumab + Azacitidine</arm_group_label>
    <other_name>JNJ-74494550</other_name>
    <other_name>ARGX-110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine at a dose 75 milligram per square meters (mg/m^2) will be administered subcutaneously or intravenously.</description>
    <arm_group_label>Part 1 (Dose Finding): Cusatuzumab + Azacitidine</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion): Cusatuzumab + Azacitidine</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For acute myeloid leukemia (AML) participants: AML according to World Health&#xD;
             Organization (WHO) 2016 criteria and fulfilling all of the following criteria:(a) more&#xD;
             than or equal to (&gt;=) 75 years of age, or younger participants who are not eligible&#xD;
             for or not willing to receive an intensive treatment (including stem cell&#xD;
             transplantation) with a curative intent and (b) previously untreated AML (except:&#xD;
             emergency leukapheresis, low dose of cytarabine and/or hydroxyurea during the&#xD;
             screening phase to control hyperleukocytosis but must be discontinued at least one day&#xD;
             prior to start of cusatuzumab [Part 1] or azacitidine [Part 2]). All trans retinoic&#xD;
             acid (ATRA) treatment for presumed acute promyelocytic leukemia (APL) is permitted but&#xD;
             must be discontinued at least 1 day prior to the start of azacitidine&#xD;
&#xD;
          -  For Myelodysplastic Syndrome (MDS) participants (only for Part 2): MDS according to&#xD;
             WHO 2016 criteria and fulfilling all of the following criteria: (a) Not eligible for&#xD;
             or not willing to receive allogenic stem cell transplantation,(b) very high or&#xD;
             high-risk MDS according to Revised International Prognostic Scoring System (IPSS-R)&#xD;
             and (c) previously untreated MDS (except: transfusion and/or cytokine therapy&#xD;
             including erythropoietin)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2&#xD;
&#xD;
          -  Must sign an informed consent form (ICF) indicating that he or she understands the&#xD;
             purpose of, and procedures required for, the study and is willing to participate in&#xD;
             the study&#xD;
&#xD;
          -  A woman of childbearing potential must have a negative highly sensitive serum (beta&#xD;
             human chorionic gonadotropin [beta hCG]) or urine pregnancy at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia (APL) with t (15;17), or its molecular equivalent&#xD;
             promyelocytic leukemia retinoic acid receptor (PML RAR alpha)&#xD;
&#xD;
          -  Leukemic involvement or clinical symptoms of leukemic involvement of the central&#xD;
             nervous system&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its&#xD;
             excipients (example, mannitol, an excipient of azacitidine)&#xD;
&#xD;
          -  Prior treatment with a hypomethylating agent for treatment of AML or MDS&#xD;
&#xD;
          -  A diagnosis of other malignancy that requires concurrent nonsurgical treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K., Japan Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunmaken Saiseikai Maebashi Hospital</name>
      <address>
        <city>Maebashi</city>
        <zip>371-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Tokyo</city>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Fukui Hospital</name>
      <address>
        <city>Yoshida</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108732</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

